

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1460, Alexandria, VA 22313-1450 on this 30 day of San Service of Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1460, Alexandria, VA 22313-1450 on this 30 day of San Service of Service of Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1460, Alexandria, VA 22313-1450 on this 30 day of San Service of Ser

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael Yeadon

Examiner: Unknown

APPLICATION NO.: 10/736,996

FILING DATE: December 16, 2003

:Group Art Unit: Unknown

TITLE: Pharmaceutical Combination

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>PURSUANT TO 37 C.F.R.</u> § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee should be required for this request. If, however, the Commissioner determines that any fee is due please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Robert T. Ronau Attorney for Applicant(s) Reg. No. 36,257

Pfizer Inc.

Patent Department, Box 8260-1611

Eastern Point Road Groton, CT 06340 (860) 441-5910

INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO. PC22050B SERIAL NO. 10/736,996 everal sheets if necessary) APPLICANT Michael Yeadon 0 2 2004 Page 1 of 1 FILING DATE December 16, 2003 **GROUP Unknown U.S. PATENT DOCUMENTS** DOCUMENT NUMBER DATE NAME SUBCLASS CLASS FILING DATE !F APPROPRIATE **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER COUNTRY CLASS SUBCLASS TRANSLATION YES OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) R. B. Dowling, et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 282, 1997, no. 3, pgs 1565-1571 L. Ottonello, et al., Clin Exp Immunol, 1996, 106: pgs 97-102 Patricia Silva, et al., British Journal of Pharmacology, 2001, 134, pgs 283-294 **EXAMINER** DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.